Amenamevir
As of the edition of 20 October 2026, Amenamevir is a small molecule: marketed, first approved in 2017 (JP).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Amenalief
- First approved
- 3 July 2017 (JP)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Maruho
- Registered trials
- 13, 1 stopped early
- Disease areas
- Infections; Skin and connective tissue; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 8 | 7 | 0 | 1 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 3 | 3 | 0 | 0 |
| All trials | 13 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Maruho | Applicant and Lead sponsor of trials | 2013 to now |